AIG, Allstate, MetLife gain on insurance demand

AIG’s shares have been volatile but resilient, closing at $76.97 on Aug. 26 after a brief summer pullback from above $84 in mid-December, with technical readings showing the stock below its 50-day moving average and an RSI of 34, a level that points to waning momentum rather than a broken long-term trend. Allstate has outperformed far more dramatically, rising to $261.81 from about $201 in late March, while MetLife has climbed to $96.52 after a strong run that briefly pushed it near $100 earlier this month.

The underlying message from the companies’ latest filings is that insurance demand has not weakened enough to offset the sector’s other positives. AIG said adjusted premiums, fees and other revenues rose 6% in the latest quarter, while MetLife reported a similar rise in adjusted premiums, fees and other revenues, helped by higher interest credited expenses and underwriting adjustments. For Allstate, the focus has remained on disciplined exposure management and catastrophe protection, which has supported investor confidence even as the stock’s recent RSI slipped to 38.3 from overbought territory.

For investors, the key question is not whether the industry can sell more coverage — it can — but whether it can do so without sacrificing margin. Stronger demand is a tailwind for top-line growth, but it also raises the stakes for reserve adequacy, catastrophe losses and claims inflation. That is particularly relevant for global insurers like AIG and MetLife, where foreign-exchange, overseas medical and travel exposures, and investment-market sensitivity can quickly alter earnings trajectories.

The expat medical case in Turkey is a reminder that cross-border insurance remains a live issue, especially for foreign residents and travelers seeking treatment away from their home systems. Any deterioration in trust around medical safety abroad can increase demand for travel, health and supplemental protection, but it can also intensify scrutiny of claims handling, policy exclusions and regulatory oversight.

The sector’s next catalyst will be whether recent premium momentum shows up in second-half earnings without a corresponding rise in losses. If pricing holds and reserves remain stable, insurers can justify current valuations. If claims costs or catastrophe losses accelerate, the recent gains in names such as Allstate could prove harder to sustain, while AIG and MetLife would likely be judged more on balance-sheet strength and capital returns than on simple revenue growth.